UPDATE – Payer Barriers Limit Timely Access

PAYER BARRIERS LIMIT TIMELY ACCESS Authored by Aurinia Pharma U.S., Inc. 

Timely access to therapy can be difficult to achieve. With Aurinia, office staff have direct support from Specialty Pharmacies (SPs) to get the medicine that their patients need.

Limited access. 

Formulary exclusions have continued to increase, leading to more prior authorizations. (1a) A physician survey has reported that prior authorization (PA) requirements have led to serious adverse events for patients in their care. (2) It has been suggested that this increase in work has led to patients abandoning their efforts to accessing their medication. (2)

Support from your SP.

The Aurinia pharmacy network offers access to treatment through Biologics by McKesson and PANTHERx. These SPs are working in concert with the Aurinia Alliance™️ team to deliver the highest level of support to ensure consistency of care for all patients. SPs can assist office staff with PA submissions, appeals, and denials, and ship the medication directly to the patient. Reach out to Aurinia Alliance or your Field Access Navigator to learn more about available services.

At Aurinia Pharma U.S., Inc., our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune diseases. Discover more about our impact on patient communities. In 2014, medicines were excluded from CVS Caremark, Express Scripts, or both. OptumRx did not begin excluding medicines from their formulary until 2016.

References: 1. Xcenda. Skyrocketing growth in PBM formulary exclusions raises concerns about patient access. September 2020. 2. American Medical Association. 2021 AMA prior authorization (PA) physician survey. 2022. https://www.ama-assn.org/system/files/prior-authorization-survey.pdf Trademarks are the property of Aurinia Pharmaceuticals Inc. Copyright ©2022, Aurinia Pharma U.S., Inc. All rights reserved. (4/22) US-LUP-2200047